Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Urogen Pharma Ltd (URGN) today and set a price target of $66. The company’s shares opened today at $41.46, close to its 52-week low of $36.95.
Archila observed:
“We remain bullish on URGN’s prospects for its lead program, MitoGel (UGN-101), as a non-surgical treatment for patients with upper tract urothelial carcinoma (UTUC), a niche, but high unmet need patient population. While we await the completion of the company’s Phase 3 OLYMPUS study for MitoGel in UTUC, we believe, post the cap raise, URGN is well positioned to execute on its near-term MitoGel initiatives (i.e. rolling NDA, commercial preparation), further its R&D efforts (i.e. VesiGel), and to potentially in-license/acquire additional assets within uro-oncology.”
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -7.4% and a 34.7% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Aimmune Therapeutics.
Currently, the analyst consensus on Urogen Pharma Ltd is a Strong Buy with an average price target of $75.75, an 82.7% upside from current levels. In a report issued on January 29, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $82 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $69.57 and a one-year low of $36.95. Currently, Urogen Pharma Ltd has an average volume of 182K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.
